Æterna Zentaris

aeternazentaris.com

Æterna Zentaris, Inc.

20 Independence Blvd 4th floor
07059 Warren, NJ
USA

Phone

aeternazentaris.com
Profile Products News

About Æterna Zentaris

Read more about Æterna Zentaris

Advertisement

Microplate reading, made easy: flexible multi-mode microplate reader with simplified assay setup
Microplate reading, made easy: flexible multi-mode microplate reader with simplified assay setup
High-Recovery Anion Exchange Membrane Chromatography for Lentiviral Vector Purification
High-Recovery Anion Exchange Membrane Chromatography for Lentiviral Vector Purification
Gentle Counterflow Centrifugation for Superior Cell Processing Results
Gentle Counterflow Centrifugation for Superior Cell Processing Results

Product portfolio of Æterna Zentaris

Product portfolio

Show all

Advertisement

3D Raman microscopes with unequalled speed, sensitivity and resolution
3D Raman microscopes with unequalled speed, sensitivity and resolution
Chemically Defined Cell Culture Media for Viral Vector and Gene Therapy Applications
Chemically Defined Cell Culture Media for Viral Vector and Gene Therapy Applications
High‑Performance Tangential Flow Filtration Solutions for Biopharmaceutical Processing
High‑Performance Tangential Flow Filtration Solutions for Biopharmaceutical Processing

News about Æterna Zentaris

Æterna Zentaris

01-Jul-2010 | research and development

Aeterna Zentaris Receives Positive Scientific Advice for its Phase 3 Trial with Perifosine in Colorectal Cancer

Aeterna Zentaris Inc. announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial ...

Read news
Æterna Zentaris

11-Jun-2010 | research and development

Aeterna Zentaris Reports Final Results of a Phase 2 Study of Perifosine in the Treatment of Colorectal Cancer

Aeterna Zentaris Inc. reported final results on the clinical activity of perifosine (KRX-0401), the Company's novel, potentially first-in-class, oral ...

Read news
Æterna Zentaris

20-May-2010 | research and development

Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for Treatment of Ovarian Cancer

Aeterna Zentaris Inc. announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal ...

Read news
Æterna Zentaris

11-May-2010 | research and development

Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer

Aeterna Zentaris Inc. announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its ...

Read news
Æterna Zentaris

12-Apr-2010 | research and development

Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer

Æterna Zentaris Inc. announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401), the Company's potentially first-in-class ...

Read news
Æterna Zentaris

07-Apr-2010 | research and development

Æterna Zentaris Announces Perifosine Receives FDA Fast Track Designation for Treatment of Refractory Advanced Colorectal Cancer

Æterna Zentaris Inc. announced that its partner, Keryx Biopharmaceuticals, was granted Fast Track designation by the U.S. Food and Drug Administration for ...

Read news
Æterna Zentaris

26-Nov-2009 | research and development

Æterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108

Æterna Zentaris Inc. announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in ...

Read news
Æterna Zentaris

24-Sep-2009 | research and development

Æterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer

Æterna Zentaris Inc. announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in ...

Read news
Æterna Zentaris

18-Sep-2009 | research and development

Æterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine

Æterna Zentaris Inc. announced that Keryx Biopharmaceuticals, Inc., its partner and licensee for perifosine in the North American market, has received ...

Read news
Æterna Zentaris

14-Aug-2008 | people

AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO

AEterna Zentaris Inc. announced the appointment of Prof. Jurgen Engel, Ph.D. as its new President and CEO, effective as of September 1, 2008. Prof. Engel ...

Read news
Æterna Zentaris

16-May-2008 | research and development

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia ( ...

Read news
Æterna Zentaris

15-Apr-2008 | people

AEterna Zentaris Announces Changes to its Management Team

AEterna Zentaris Inc. announced that David J. Mazzo, Ph.D., has resigned as President and Chief Executive Officer and as member of the Board of Directors ...

Read news
Æterna Zentaris

01-Nov-2007 | business & finance

Jado Technologies licences clinical data from Æterna Zentaris for use of Miltefosine in allergy indications

Dresden based biotech JADO Technologies today signed an agreement with Aeterna Zentaris for access to clinical data for the marketed drug miltefosine. JADO ...

Read news
Æterna Zentaris

29-Oct-2007 | research and development

AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112

AEterna Zentaris Inc. presented an abstract outlining novel data generated from three AEZS-112 (formerly ZEN-012) follow-up multi-targeted cytotoxic ...

Read news
Æterna Zentaris

21-Aug-2007 | people

Æterna Zentaris Completes Management Team with the Appointment of Chief Medical Officer

Æterna Zentaris Inc. announced the filling of a key position completing the management team with the appointment of Paul Blake, M.D., as Senior Vice ...

Read news
Show more news about Æterna Zentaris

Advertisement

Screening and Purification for Large Biomolecules in Multi-Well Plate Design
Screening and Purification for Large Biomolecules in Multi-Well Plate Design
Streamlined Single-Use TFF Platform for Process Development Through Pilot Manufacturing
Streamlined Single-Use TFF Platform for Process Development Through Pilot Manufacturing
Maximum binding capacity in ion exchange chromatography
Maximum binding capacity in ion exchange chromatography

Here you will find Æterna Zentaris, Inc.